We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Two Cytokines Regulate Development of Immune System Memory Cells

By LabMedica International staff writers
Posted on 09 Jun 2009
The process of developing new vaccines should be facilitated by the discovery that two different cytokines regulate the formation of the CD8+ T-cells that "remember” pathogens and allow the immune system to quickly respond to any subsequent infection.

Investigators from the University of Texas Southwestern Medical School (Dallas, USA) studied how two cytokines, interleukin-21 (IL-21) and interferon, affected the development of immune T-cells in response to infection. More...
They reported in the May 28, 2009, issue of the journal Blood that IL-12 exclusively promoted the development of interferon-gamma and tumor necrosis factor (TNF) secreting T effector memory (TEM) cells, whereas interferon drove the development of T central memory (TCM) cells.

The development of TEM and TCM was linked to cell division. In rapidly dividing cells, IL-12 programmed TEM through induction of the IL-12 receptor beta-2. In contrast, interferon regulated TCM development by slowing the progression of cell division in a subpopulation of cells that selectively expressed elevated interferon receptor-2. In the presence of both IL-12 and interferon, these cytokine signals promoted the simultaneous development of both TCM and TEM.

"Until now, no innate signals have been identified that regulate the development of memory cells,” said senior author Dr. David Farrar, assistant professor of immunology at the University of Texas Southwestern Medical Center. "Our study is the first to identify the signals that promote the development of these memory cells when you first get infected. Regardless of the precise mechanism, what we know now is that you can develop both long-term and immediate memory cells at the same time.”

"There are some vaccines that are extremely effective, while others are only moderately effective,” Dr. Farrar said. "If we can isolate pools of antigen-specific memory cells, we should be able to determine what it is about those pools of memory cells that is different between an extremely effective vaccine and one that's not so effective. If we can figure that out, then we can start to think about altering our approach to vaccinating based on the different type of microorganism that we're trying to vaccinate against.”

Related Links:
University of Texas Southwestern Medical School



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.